Payment overview · 2025
General Payments
$230.30
13 reported records · 7 companies
Healthcare provider profile · identity verified
Chandrakant N Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PORT ST LUCIE, FL · NPI 1760438527
Verified facts
What the public records show
CMS Open Payments records show Chandrakant N Patel, MD received $230.30 in general payments during 2025 across 13 reported records.
Amgen Inc. accounted for 36.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $84.93 | 36.9% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.39 | 15.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.20 | 15.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.40 | 9.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.53 | 7.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.23 | 7.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.62 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $230.30 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $70.17 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 529 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 526 | 167 |
| Levothyroxine Sodium | Levothyroxine Sodium | 359 | 104 |
| Lisinopril | Lisinopril | 337 | 105 |
| Losartan Potassium | Losartan Potassium | 325 | 96 |
| Omeprazole | Omeprazole | 294 | 104 |
| Metformin Hcl | Metformin Hcl | 269 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 254 | 83 |
| Simvastatin | Simvastatin | 237 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 72 |
| Gabapentin | Gabapentin | 181 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 155 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 55 |
| Carvedilol | Carvedilol | 127 | 39 |
| Furosemide | Furosemide | 127 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 37 |
| Atenolol | Atenolol | 117 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 37 |
| Alprazolam | Alprazolam | 87 | 22 |
| Eliquis | Apixaban | 86 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 30 |
| Sertraline Hcl | Sertraline Hcl | 73 | 22 |
| Ezetimibe | Ezetimibe | 72 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 18 |
| Allopurinol | Allopurinol | 69 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 22 |
| Famotidine | Famotidine | 68 | 24 |
| Lorazepam | Lorazepam | 66 | 12 |
| Potassium Chloride | Potassium Chloride | 65 | 27 |
| Diazepam | Diazepam | 64 | 14 |
| Glimepiride | Glimepiride | 64 | 20 |
| Clonazepam | Clonazepam | 63 | 16 |
| Januvia | Sitagliptin Phosphate | 61 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 17 |
| Glipizide | Glipizide | 59 | 20 |
| Fenofibrate | Fenofibrate | 58 | 20 |
| Montelukast Sodium | Montelukast Sodium | 57 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 18 |
| Finasteride | Finasteride | 52 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 17 |
| Meloxicam | Meloxicam | 48 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 17 |
| Glipizide Er | Glipizide | 45 | 12 |
| Jardiance | Empagliflozin | 43 | suppressed |
| Lovastatin | Lovastatin | 43 | 13 |
| Telmisartan | Telmisartan | 43 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 13 |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 16 |
| Nifedipine Er | Nifedipine | 40 | 11 |
| Meclizine Hcl | Meclizine Hcl | 38 | 12 |
| Memantine Hcl | Memantine Hcl | 37 | 11 |
| Synthroid | Levothyroxine Sodium | 35 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 16 |
| Temazepam | Temazepam | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 12 |
| Clonidine Hcl | Clonidine Hcl | 30 | 14 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | 11 |
| Azithromycin | Azithromycin | 28 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $230.30 · 13 records | Amgen Inc. | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, EVENITY, INTELLIS ADAPTIVESTIM, JARDIANCE, LEQVIO, MOUNJARO, OTEZLA, PROLIA, REPATHA, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error